Literature DB >> 14706336

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Sunil R Hingorani1, Emanuel F Petricoin, Anirban Maitra, Vinodh Rajapakse, Catrina King, Michael A Jacobetz, Sally Ross, Thomas P Conrads, Timothy D Veenstra, Ben A Hitt, Yoshiya Kawaguchi, Don Johann, Lance A Liotta, Howard C Crawford, Mary E Putt, Tyler Jacks, Christopher V E Wright, Ralph H Hruban, Andrew M Lowy, David A Tuveson.   

Abstract

To evaluate the role of oncogenic RAS mutations in pancreatic tumorigenesis, we directed endogenous expression of KRAS(G12D) to progenitor cells of the mouse pancreas. We find that physiological levels of Kras(G12D) induce ductal lesions that recapitulate the full spectrum of human pancreatic intraepithelial neoplasias (PanINs), putative precursors to invasive pancreatic cancer. The PanINs are highly proliferative, show evidence of histological progression, and activate signaling pathways normally quiescent in ductal epithelium, suggesting potential therapeutic and chemopreventive targets for the cognate human condition. At low frequency, these lesions also progress spontaneously to invasive and metastatic adenocarcinomas, establishing PanINs as definitive precursors to the invasive disease. Finally, mice with PanINs have an identifiable serum proteomic signature, suggesting a means of detecting the preinvasive state in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14706336     DOI: 10.1016/s1535-6108(03)00309-x

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  1112 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Brandy Edenfield; Lizhi Zhang; David W Dawson; Peter Storz
Journal:  Cancer Discov       Date:  2014-10-31       Impact factor: 39.397

3.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

4.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

7.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

8.  Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells.

Authors:  Mourad Ferdaoussi; Xiaoqing Dai; Mette V Jensen; Runsheng Wang; Brett S Peterson; Chao Huang; Olga Ilkayeva; Nancy Smith; Nathanael Miller; Catherine Hajmrle; Aliya F Spigelman; Robert C Wright; Gregory Plummer; Kunimasa Suzuki; James P Mackay; Martijn van de Bunt; Anna L Gloyn; Terence E Ryan; Lisa D Norquay; M Julia Brosnan; Jeff K Trimmer; Timothy P Rolph; Richard G Kibbey; Jocelyn E Manning Fox; William F Colmers; Orian S Shirihai; P Darrell Neufer; Edward T H Yeh; Christopher B Newgard; Patrick E MacDonald
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

Review 9.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

10.  KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

Authors:  Alexandros Tzatsos; Polina Paskaleva; Francesco Ferrari; Vikram Deshpande; Svetlana Stoykova; Gianmarco Contino; Kwok-Kin Wong; Fei Lan; Patrick Trojer; Peter J Park; Nabeel Bardeesy
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.